论文部分内容阅读
目前,神经垂体素(垂体后叶素)仍为治疗咯血的首选药,但对于有冠心病、高血压、妊娠、肺心病患者有较多的不良反应,有一定的危险性。我们参考文献资料[1]大胆使用缩宫素治疗咯血,与神经垂体素相比,具有用药简单、安全、疗效可靠等优点。现就临床应用情况报告如下:1 对象与方法1.1 对象共观察咯血病人36例,其中男性25例,女性11例;14～20岁5例,20～40岁18例,40岁以上者13例。根据文献[2]分为:肺结核咯血21
At present, neurophysin (vasopressin) is still the first choice for the treatment of hemoptysis, but for patients with coronary heart disease, hypertension, pregnancy, pulmonary heart disease have more adverse reactions, there is a certain risk. We reference [1] bold use of oxytocin treatment of hemoptysis, compared with neurophysin, with medication is simple, safe, reliable and so on. Now on the clinical application of the report are as follows: 1 objects and methods 1.1 objects were observed in 36 cases of hemoptysis, including 25 males and 11 females; 14 to 20 years in 5 cases, 20 to 40 years in 18 cases, 40 years of age in 13 cases . According to the literature [2] is divided into: tuberculosis hemoptysis 21